In detail, patients in the 4th quartile for their content of PD1+ EVs from CD8+ T cells and PD-L1+ EVs from melanoma showed a higher risk to have a shorter PFS (p = 0.038 and p = 0.004, respectively). The gene discussed is CD8A; the disease is melanoma.